Literature DB >> 7115473

Elevated lipoprotein lipase activity in skeletal muscle tissue during treatment of hypertriglyceridaemic patients with bezafibrate.

B Vessby, H Lithell, H Ledermann.   

Abstract

Eleven hypertriglyceridaemic patients were treated with 600 mg bezafibrate daily for 2 months. The mean serum triglyceride concentration decreased by 35% (P less than 0.01) corresponding to a reduction in the very low density lipoprotein triglycerides by 41% (P less than 0.01). The high density lipoprotein cholesterol concentration and the serum concentration of apolipoproteins AI and AII increased by 19% (P less than 0.02), 11% (N.S., P less than 0.08) and 24% (P less than 0.01), respectively. The fractional removal rate (K2) in the intravenous fat tolerance test (IVFTT) increased by 37% (P less than 0.001). This was associated with significant increase of the skeletal muscle lipoprotein lipase activity ( + 39%, P less than 0.05). The mean value for the adipose tissue lipoprotein lipase activity remained unchanged. The K2 at IVFTT was correlated highly significantly to the activity of skeletal muscle lipoprotein lipase (r = 0.85, P less than 0.01). The present study indicates that the main reason for the reduction of the serum triglycerides during treatment with bezafibrate may be an increased activity of the skeletal muscle tissue lipoprotein lipase activity.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7115473     DOI: 10.1016/0021-9150(82)90057-0

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  9 in total

1.  Apolipoprotein A and B (Sf 100-400) metabolism during bezafibrate therapy in hypertriglyceridemic subjects.

Authors:  J Shepherd; C J Packard; J M Stewart; R F Atmeh; R S Clark; D E Boag; K Carr; A R Lorimer; D Ballantyne; H G Morgan
Journal:  J Clin Invest       Date:  1984-12       Impact factor: 14.808

2.  Combination treatment with cholestyramine and bezafibrate for heterozygous familial hypercholesterolaemia.

Authors:  L D Curtis; A C Dickson; K L Ling; J Betteridge
Journal:  BMJ       Date:  1988-07-16

3.  Pharmacological effects of lipid-lowering drugs on circulating adipokines.

Authors:  Desiree Wanders; Eric P Plaisance; Robert L Judd
Journal:  World J Diabetes       Date:  2010-09-15

4.  Stimulation of decreased lipoprotein lipase activity in the tumor-bearing state by the antihyperlipidemic drug bezafibrate.

Authors:  K Nomura; Y Noguchi; A Matsumoto
Journal:  Surg Today       Date:  1996       Impact factor: 2.549

5.  Abnormalities in very low, low and high density lipoproteins in hypertriglyceridemia. Reversal toward normal with bezafibrate treatment.

Authors:  S Eisenberg; D Gavish; Y Oschry; M Fainaru; R J Deckelbaum
Journal:  J Clin Invest       Date:  1984-08       Impact factor: 14.808

6.  Effects of clofibrate, bezafibrate, fenofibrate and probucol on plasma lipolytic enzymes in normolipaemic subjects.

Authors:  F Heller; C Harvengt
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

Review 7.  Bezafibrate. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hyperlipidaemia.

Authors:  J P Monk; P A Todd
Journal:  Drugs       Date:  1987-06       Impact factor: 9.546

8.  High-density lipoprotein and apolipoprotein A-I deficiency induced by combination therapy with probucol and bezafibrate.

Authors:  K Saku; B Zhang; S Jimi; H Bai; K Hirata; N Sasaki; R Liu; K Arakawa
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

9.  The effects of clofibrate and bezafibrate on cholesterol metabolism in the liver of the male rat.

Authors:  J H Shand; D W West
Journal:  Lipids       Date:  1994-11       Impact factor: 1.880

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.